DNA免疫吸附联合药物治疗重度系统性红斑狼疮的近期疗效观察  

The short-term therapeutic effects of DNA immunoadsorbent combined with medication on patients with ;severe systemic lupus erythematosus

作　　者：吴潮清[1] 熊礼佳[1] 贺红光[1] 刘芸芳[1] 李瑾瑜[1] 王浩宇[1] 唐盛[1] 叶琨[1] 彭小梅[1] 黄玲[1] 唐业莹[1] 

机构地区：[1]广西壮族自治区人民医院泌尿内科,广西 南宁530021

出　　处：《中国中西医结合急救杂志》2014年第2期84-87,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：基金项目：广西自然科学基金资助项目（桂科自099199）

摘　　要：目的：观察DNA免疫吸附联合激素和免疫抑制剂治疗重度系统性红斑狼疮（SLE）的近期疗效。方法选择32例重度活动期SLE患者，采用DNA免疫吸附联合糖皮质激素＋环磷酰胺治疗，免疫吸附治疗共3次，每次2.5 h，间隔24～48 h进行随后的2次免疫吸附。治疗前及吸附治疗结束2周后观察SLE疾病活动度指数（SLEDAI）评分、健康状况评价指标〔生理功能（PF）和精神健康（MH）评分〕、肾功能指标〔血尿素氮（BUN）和血清肌酐（SCr）〕的变化；并检测抗双链DNA抗体（dsDNA）、免疫球蛋白（IgA、IgG、IgM）、补体（C3和C4）、超敏C-反应蛋白（hs-CRP）等变化。结果联合用药治疗2周后，患者SLEDAI评分、BUN、SCr、dsDNA、IgA、IgG、IgM、hs-CRP均较治疗前明显降低〔SLEDAI评分（分）：14.38±3.85比15.69±1.40，BUN （mmol/L）：11.22±4.78比16.31±7.90，SCr（μmol/L）：127.02±38.17比167.25±45.63，dsDNA（U/L）：1.36±0.12比1.43±0.18，IgA（g/L）：2.41±0.73比2.59±0.86，IgG（g/L）：16.82±4.83比21.01±4.84，IgM（g/L）：1.64±0.45比1.75±0.58，hs-CRP（mg/L）：14.41±2.20比14.94±2.60，P＜0.05或P＜0.01〕；PF评分、MH评分、C3均升高〔PF评分（分）：71.19±17.53比56.66±22.41，MH评分（分）：74.01±15.72比61.50±17.98，C3（g/L）：0.56±0.09比0.52±0.10，均P＜0.05〕；临床症状明显好转，无明显不良反应发生。结论免疫吸附联合药物治疗重度活动期SLE近期疗效显著，能降低dsDNA、IgA、IgG、IgM、hs-CRP水平，升高补体C3水平。Objective To evaluate the short-term therapeutic effects of DNA immunoadsorbent （IA） combined with glucocorticoid and immune depressant on patients with severe systemic lupus erythematosus（SLE）. Methods 32 patients with severe SLE were selected to undergo DNA IA treatment combined with glucocorticoid plus cyclophosphamide therapy, and each patient received IA therapy 3 times, once 2.5 hours, with an interval of 24-48 hours to take another two times of IA. The changes in SLE disease activity index（SLEDAI）score, health status evaluation indexes〔 physiologic functional（ PF） and emotional health（ MH） scores〕,renal function indexes〔 blood urea nitrogen（BUN）and serum creatinine（SCr）〕 were observed; and anti-double stranded DNA antibody（ ds-DNA）, immunoglobulin （IgA, IgG, IgM）, complements（C3 and C4）and high-sensitivity C-reactive protein （hs-CRP） were examined before and after IA treatment for 2 weeks. Results Two weeks after the combination therapy, the SLEDAI score, BUN, SCr, dsDNA, IgA, IgG, IgM, hs-CRP were significantly lower than those before treatment 〔SLEDAI score ： 14.38±3.85 vs. 15.69±1.40, BUN （mmol/L）： 11.22±4.78 vs. 16.31±7.90, SCr （μmol/L）： 127.02±38.17 vs. 167.25±45.63, dsDNA（ U/L）： 1.36±0.12 vs. 1.43±0.18, IgA（ g/L）： 2.41±0.73 vs. 2.59±0.86, IgG（ g/L）： 16.82±4.83 vs. 21.01±4.84, IgM（ g/L）： 1.64±0.45 vs. 1.75±0.58, hs-CRP（ mg/L）： 14.41±2.20 vs. 14.94±2.60, P〈0.05 or P〈0.01〕; PF score, MH score, complement C3 were increased〔 PF score ： 71.19±17.53 vs. 56.66±22.41, MH score ： 74.01±15.72 vs. 61.50±17.98, C3（ g/L）： 0.56±0.09 vs. 0.52±0.10, all P〈0.05〕; clinical symptoms were improved significantly, and no significant adverse reactions were found. Conclusion IA combined with medical treatment has shown that it has significant therapeutic effect for treatment of patients with severe SLE, and it may decrease the levels of dsDNA, IgA, IgG, IgM,hs-CRP, and increase the le

关 键 词：DNA免疫吸附 系统性红斑狼疮疾病活动度评分 健康状况评价 抗双链DNA抗体 免疫球蛋白 超敏C-反应蛋白 补体 

分 类 号：R72[医药卫生—儿科]